Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
88 hedge funds and large institutions have $256M invested in Accelerate Diagnostics in 2015 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 12 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2% more funds holding
Funds holding: 86 → 88 (+2)
36% less capital invested
Capital invested by funds: $400M → $256M (-$144M)
62% less call options, than puts
Call options by funds: $1.19M | Put options by funds: $3.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$5.5M |
| 2 |
Millennium Management
New York
|
+$2.83M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.75M |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$1.34M |
| 5 |
DA
DSC Advisors
Chicago,
Illinois
|
+$814K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$4.07M |
| 2 |
CCM
Cupps Capital Management
Chicago,
Illinois
|
-$2.83M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
-$2.6M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.72M |
| 5 |
Bank of New York Mellon
New York
|
-$795K |
AXDX Hedge Fund Activity: Q3 2015 in Review
88 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2015, worth a combined $256M — down 36% from $400M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AXDX positions and 12 closed out — a net gain of 2 holders — while 32 added to existing stakes and 20 trimmed.
The largest buyer was Nuveen, opening a new position worth an estimated $5.5M. The largest seller was William Blair & Company, cutting an estimated $4.07M.
- 88 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2015, up from 86 in Q2 2015.
- Funds reported $256M of Accelerate Diagnostics stock for Q3 2015, down 36% quarter-over-quarter.
- 14 funds opened new Accelerate Diagnostics positions in Q3 2015 and 12 closed out, a net change of +2 holders.
- The largest Accelerate Diagnostics buyer in Q3 2015 was Nuveen, an estimated $5.5M added.
- The largest Accelerate Diagnostics seller in Q3 2015 was William Blair & Company, an estimated $4.07M sold.
Based on aggregated 13F filings for Q3 2015.